The short answer
DL-alpha-lipoic acid warrants glucose review during insulin-aspart treatment, but the exact combination has not been shown to cause hypoglycemia in a clinical trial. Its reported autoimmune low-glucose risk is a separate issue.
What this answer covers
Oral DL racemate; R-alpha-lipoic acid and unspecified ALA products are not automatically equivalent. Subcutaneous or supervised intravenous insulin aspart is distinct from endogenous insulin.
- Supplement or preparation
- DL-alpha-Lipoic acid
- Medication ingredient
- insulin aspart, human
A racemic preparation changed insulin sensitivity
A short pilot trial of oral RAC-alpha-lipoic acid found increased insulin-stimulated glucose disposal. This offers a reason to review glucose response, but a clamp result is not a measured hypoglycemia event or an aspart interaction.
Autoimmune cases answer a different question
Cases of alpha-lipoic-acid-associated insulin autoimmune syndrome describe an antibody-related cause of low glucose. They do not demonstrate increased action of injected insulin aspart, and the inspected abstract does not verify the DL formulation.
The current monograph retains a precaution
Health Canada’s monograph identifies DL and R forms and advises consultation in diabetes, with low-glucose symptom warnings for covered products. Its labeling conditions should not be read as a guaranteed safe dose boundary.
Respond to changes without guessing insulin adjustments
Discuss the exact product and dose with the diabetes team before starting or stopping it. Follow your agreed glucose-monitoring and low-glucose treatment plan; do not adjust insulin on your own. Unexpected or recurrent lows need assessment rather than assuming every episode is a routine dose effect.
Evidence and practical considerations
Side effects & toxicity
Exact additive insulin-aspart hypoglycemia is unestablished; racemate insulin-sensitivity evidence and separate autoimmune reports support a narrower monitoring precaution, not the claimed clinical interaction.
- Exact scope
- Oral DL racemate; R-alpha-lipoic acid and unspecified ALA products are not automatically equivalent. Subcutaneous or supervised intravenous insulin aspart is distinct from endogenous insulin. with Insulin aspart human RxCUI51428 IN; NovoLog/Fiasp formulation and subcutaneous/pump/supervised intravenous routes distinguished.
- Medication form and route
- injected insulin aspart; oral supplement
What remains uncertain
- No source-specific uncertainty removed; no invented event rate or universal insulin adjustment.
Factors that may matter: Exact insulin product; Meal pattern; Dose; Other diabetes treatment; Kidney and liver function; Supplement preparation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 74people with type2diabetes.
Pooled active racemic alpha-lipoic-acid groups had increased insulin-stimulated glucose disposal versus placebo.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Exploratory pilot and pooled active doses, no insulin-aspart regimen or clinical hypoglycemia incidence; insulin sensitivity is not itself an adverse event.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two women with insulin autoimmune syndrome.
Two women developed insulin autoimmune syndrome associated with alpha-lipoic acid; genetic susceptibility identified.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Case reports do not prove an insulin-aspart interaction; exact stereochemical preparation not established in abstract. Autoimmune endogenous-insulin mechanism distinct from additive injected-insulin action.
Source 5: current natural-health-product monograph
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: Adults considering covered alpha-lipoic-acid products.
Covered products require diabetes consultation advice and low-glucose symptom precautions under stated labeling conditions.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Labeling thresholds are not proven safe-dose cutoffs. Not an aspart-specific interaction study.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact insulin-aspart article with product, route, botanical and clinical endpoint boundaries. | |
| Research summary published |
Article revision: 2018a1ad79e8bb95
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.